Monday, 31 August 2026European Markets

HOFSETH BIOCARE Stock Rises 9% So Far On Friday, Outperforms Market

Loading stream...

At 11:43 EST on Friday, shares of HOFSETH BIOCARE (HBC.OL) surged by 9.83% to close at kr3.24 at 11:43 EST - marking an upward movement from their last closing price at kr2.95. Although still 25.32% below their 52-week high of kr3.95, the increase suggests the stock is moving in an optimistic manner similar to Oslo Bors Benchmark Index_GI as a whole.

About Hofseth BioCare ASA

Hofseth BioCare ASA of Alesund, Norway serves as a provider of pet and consumer health ingredients both within Norway and internationally. Products offered include Brilliant and OmeGo salmon oils as well as ProGo Salmon Protein Powder.

Financial Health Concerns

However, despite HBC.OL's stock rally, its financial health remains cause for serious concern. Over the past year it reported negative earnings per share of kr-0.37 and its return on equity is also disconcertingly negative at 126.49% indicating significant shareholder equity losses.

Stock Stability

On a positive note, however, the value of HOFSETH BIOCARE's shares remains well above its 50-day moving average of kr2.87 and slightly above its 200-day moving average of kr2.96, suggesting relative mid- to long-term stability.

Revenue Growth and Profitability

As well, the company has witnessed impressive revenue growth; its year-on-year quarterly revenue growth increased by 45.4% year over year to reach 134.43 million during its twelve trailing months period. Unfortunately, however, EBITDA stands at a negative number at -39.65; thus raising concerns over its profitability.

Conclusion

Overall, HOFSETH BIOCARE's stock performance indicates an upward trajectory with promising revenue growth and worrying profitability metrics that call attention to the need for strategic decision-making in order to enhance shareholder returns and bolster overall financial status.

More news about HOFSETH BIOCARE (HBC.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Hawkish Fed Signals at Jackson Hole Pressure Rate-Sensitive Assets
Kevin Warsh's hawkish inflation remarks at Jackson Hole, alongside a steady drumbeat of Federal Reserve testimony from Powell, Barr, Bowman and other officials on supervision, regulation and monetary policy, signal continued vigilance against inflation rather than an imminent easing cycle. Rate-sensitive and precious-metals-linked names such as SSR Mining sold off the same day, consistent with markets repricing for a firmer-for-longer policy stance.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,979
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,979 facts checked against source5,261 source documents archived
Query this data → isubstrate.com